BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Cue Biopharma Inc. (NASDAQ: CUE) witnessed a dramatic sell-off in its stock price after the clinical-stage biotechnology firm disclosed the terms of a substantial public equity offering. The ...

Cue Biopharma Inc. Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include ...

Oil and gas exploration, development and production.

Find the latest Cue Biopharma, Inc. (CUE) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.